Not staying at full therapeutic dose forever
Novo Nordisk is awaiting new approvals for their oral semaglutide products
Biological agent reference sheet: Clostridium beijerinckii
expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations
GLP-1 drugs are expensive 2 , retailing for as much as $16,000 per year
[32] (PIONEER trials) further highlighted that diarrhea was dose-dependent and often controllable with loperamide
